Displaying drugs 1376 - 1400 of 2034 in total
Marzeptacog alfa (activated)
Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
Investigational
TMC-310911
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to...
Investigational
Matched Description: … investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
GC-376 free acid
GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov...
Experimental
Matched Description: … These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19. …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Isoquercitrin
Isoquercitrin is under investigation in clinical trial NCT04622865 (Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19).
Investigational
Matched Description: … With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 …
Plutavimab
Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Investigational
Matched Description: … Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 …
Metelimumab
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
Tarcocimab tedromer
Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)).
Investigational
Galidesivir
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and...
Investigational
Matched Description: … Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
DG031
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
Investigational
KB002
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
PRX-07034
Investigational
GLPG-0259
GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability and Food Effect).
Investigational
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
PBR-06 F-18
Investigational
NRC-AN-019
Investigational
SNS01-T
SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Investigational
RR001
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
TTAX01
TTAX01 is a cryopreserved human umbilical cord product being developed by TissueTech.
Investigational
ALMB-0166
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
NX001
Investigational
EB003
EB003 is a CRISPR-based sequence-specific antimicrobial (SSAM) targeted against shiga toxin-producing E. coli.
Investigational
PBGM01
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
Sasanlimab
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Displaying drugs 1376 - 1400 of 2034 in total